Triple Negative Breast Cancer

TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...

FOSTER CITY, Calif., July 24, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...

SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...

FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...

FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...

Redmond, Washington, USA – May 21, 2026 SystImmune, Inc. announced that multiple clinical and late-stage development data sets from...

FREMONT, California, May 20, 2026 Personalis announced that the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program...

Washington, D.C. – May 15, 2026 Tigerlily Foundation announced a new collaboration with Bristol Myers Squibb focused on improving...

RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...